Accuray Incorporated (NASDAQ: ARAY) and Samsung NeuroLogica are pursuing advanced volumetric imaging capabilities for the CyberKnife radiation therapy platform, combining mobile CT technology with robotic radiosurgery and real-time motion management.
The companies have entered agreements to evaluate how Samsung NeuroLogica’s mobile computed tomography (CT) and volumetric imaging technology could be integrated with Accuray’s CyberKnife System. The collaboration is being highlighted at the American Society for Radiation Oncology (ASTRO) Annual Meeting in Boston, which runs from Sept. 26 through Sept. 30.
The initiative is aimed at bringing additional three-dimensional imaging information closer to the point of treatment. Accuray said clinicians have identified enhanced imaging and treatment-room visualization as areas that could improve treatment efficiency and support decision-making.
The companies are combining Samsung NeuroLogica’s experience in mobile CT with Accuray’s capabilities in precision radiation delivery, robotic radiosurgery and motion management. The objective is to evaluate whether volumetric imaging can complement CyberKnife’s existing treatment workflow.
Focus on Anatomy During Treatment
CyberKnife uses robotic radiation delivery and image guidance to deliver radiation to targets while accounting for movement. Accuray has highlighted real-time motion management as an important component of its technology, including for moving targets such as lung tumors.
Volumetric imaging could provide clinicians with a broader view of the target and surrounding anatomy at the time of treatment. The companies said this could potentially provide additional information for treatment decisions and, further ahead, support approaches that account for changes in patient anatomy during a treatment course.
Nicholas van As, consultant clinical oncologist at The Royal Marsden NHS Foundation Trust, said the ability to see the target and surrounding anatomy together during treatment could support more informed clinical decisions.
The Royal Marsden is participating as the first center worldwide in the Accuray-Samsung NeuroLogica collaboration, according to Accuray. The work will explore how Samsung’s volumetric imaging technology could be applied alongside robotic radiosurgery.
Potential Applications Across Multiple Cancers
The companies said the potential applications extend across thoracic, abdominal and pelvic cancers.
Jonathan Lischalk, clinical director of radiosurgery at MedStar Georgetown University Hospital and clinical associate professor at Georgetown University School of Medicine, said volumetric imaging could provide additional information for clinicians treating lung, pancreatic and prostate cancers.
For these treatments, understanding the position of a tumor relative to surrounding healthy organs can be important in determining radiation delivery. Additional imaging during treatment could therefore complement CyberKnife’s non-coplanar radiation delivery and motion-management capabilities, according to the companies.
The longer-term possibility under evaluation is adaptive treatment, in which treatment parameters can be adjusted in response to changes in patient anatomy. However, the current collaboration remains at the development and evaluation stage, and Accuray has not announced a commercial product.
Samsung Brings Mobile CT Expertise
Samsung NeuroLogica’s contribution centers on mobile CT technology, which is designed to bring volumetric imaging directly to patients rather than requiring them to move between separate imaging and treatment environments.
“Our team has spent years developing mobile CT, bringing imaging to the patient,” said Boris Geyzer, head of Business, Mobile CT, Samsung HME America. He said the collaboration is focused on the practical clinical need for improved visualization of anatomy in the treatment room.
The initiative follows an earlier agreement between Samsung HME America and Accuray to explore potential cooperation around precision radiation therapy solutions based on volumetric imaging. Samsung had identified its BodyTom mobile CT and Accuray’s CyberKnife platform as technologies that could potentially be combined for image-guided therapy.
Part of Accuray’s Partnership Strategy
Accuray is positioning the collaboration as part of a broader strategy to combine internally developed technologies with external partnerships rather than developing every capability in-house.
“When I joined Accuray, I spoke about the importance of bringing meaningful innovation to customers with greater focus and speed,” said Steve La Neve, president and CEO of Accuray. He said the company is evaluating where it should develop technology internally and where collaboration can bring complementary expertise to customer needs.
The company has pursued other technology partnerships in 2026. Earlier in September, Accuray agreed to collaborate with RaySearch Laboratories on integrating RayStation treatment-planning software with Accuray platforms to advance online adaptive radiation therapy capabilities.
Development Remains Subject to Evaluation
The Accuray-Samsung NeuroLogica collaboration will proceed through phased development activities covering technical, clinical and commercial considerations. Any future product or clinical application will also be subject to applicable regulatory requirements.
Accuray emphasized that no commercial product offering has been announced as part of the collaboration. The companies are currently assessing the technology and potential clinical workflows rather than announcing a market-ready imaging solution.
The collaboration comes as radiation oncology increasingly combines imaging, treatment planning and delivery technologies to provide clinicians with more information during procedures. For Accuray, the work could add volumetric imaging to the capabilities surrounding CyberKnife’s robotic delivery and motion-management platform, while Samsung NeuroLogica gains an opportunity to explore applications for mobile CT in radiation treatment environments.
The companies are presenting the collaboration during ASTRO 2026 in Boston, where Accuray is also showcasing its CyberKnife and other radiation therapy technologies.
